Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study


Por: Requena, GA, Rodríguez-Veiga, R, Gil, C, Botella, C, Aguiar, E, Trigo, F, Colorado, M, del Castillo, TD, Barragan, E, Tormo, M, Arbolí, ER, López, JS, Boyero, RG, Castaño, T, Puente, PH, Riquelme, MAR, Lloris, MJS, Algarra-Algarra, L, Rodriguez-Medina, C, Melo, CLS, Gomez, JL, Vives, S, Salamero, O, Amigo, ML, Nuñez, MV, Rojas, C, Bass, F, García-Fortes, M, Vicente, BV, Polo, M, Benavente, C, Madrigal, MD, Espinoza, M, Pérez-Encinas, M, Barciela, MLA, Bautista, G, Solana-Altabella, A, Cano-Ferri, I, Colmenares, R, García-Ramírez, P, Alis, FI, García, MB, Rodríguez-Macías, G, López, M, Hernández, AYO, Cerveró, CJ, Martínez-Cuadrón, D, Chorao, P, Burgues, JMB and Montesinos, P

Publicada: 22 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
In a large multicenter real-world cohort, we aimed to evaluate outcomes of FLAG-Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998-2024), including patients with primary refractory disease (36.9%) and first relapse episode (63.1%), with a median age of 52 years. Complete remission composite (CRc) was achieved 56.8%, including complete remission (CR) in 51.0%, CR with incomplete recovery in 4.0%, and morphological-free-state in 1.8%, enabling 35.2% of patients and 62% of responders to proceed to allogeneic transplantation without morphological disease. With median follow-up of 50.9 months, median overall survival (OS) was 10.2 months, with 5-year OS rate of 21.6%. Prior allogeneic transplantation (HR 0.54; p < 0.001) and relapse-free interval >= 1 year (HR 0.75; p = 0.024) independently predicted improved OS, whereas modified high-risk cytogenetics including t(8; 21) (HR 3.58; p < 0.001), FLT3-ITD mutation at primary diagnosis (HR 1.61; p < 0.001), and age >= 60 (HR 1.43; p < 0.001) conferred inferior OS. Validation of the SALFLAGE score demonstrated moderate discrimination (C-index 0.67), with 5-year survival of 38.4%, 27.2%, and 12.7% across risk categories (p < 0.001). Outcomes improved over periods (1998-2005 vs. 2006-2016 vs. 2017-2024): 30-day mortality was 6.9% vs. 9.3% vs. 5.0%, respectively (p = 0.030), and median OS was 7.8 versus 9.4 versus 11.1 months, respectively (p = 0.16). We confirm FLAG-Ida as a reference salvage regimen in fit R/R AML and validate the SALFLAGE score in this setting.

Filiaciones:
Requena, GA:
 Montpellier Univ Hosp, Serv Hematol Clin, Montpellier, France

 Univ Montpellier, Montpellier, France

Rodríguez-Veiga, R:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Gil, C:
 Hosp Gen Alicante, Serv Hematol, Alicante, Spain

Botella, C:
 Hosp Gen Alicante, Serv Hematol, Alicante, Spain

Aguiar, E:
 Ctr Hosp Sao Joao, Serv Hematol, Porto, Portugal

Trigo, F:
 Ctr Hosp Sao Joao, Serv Hematol, Porto, Portugal

Colorado, M:
 Hosp U Marques de Valdecilla, Serv Hematol, Santander, Spain

del Castillo, TD:
 Hosp Cent Asturias, Serv Hematol, Oviedo, Spain

Barragan, E:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Tormo, M:
 Hosp Clin Univ Valencia, Serv Hematol, Valencia, Spain

Arbolí, ER:
 Hosp U Virgen del Rocio, Serv Hematol, Seville, Spain

López, JS:
 Hosp Reina Sofia, Serv Hematol, Cordoba, Spain

Boyero, RG:
 Hosp Gen Castellon, Serv Hematol, Castellon de La Plana, Spain

Castaño, T:
 Hosp Fdn Jimenez Diaz, Serv Hematol, Madrid, Spain

Puente, PH:
 Hosp Ramon & Cajal, Serv Hematol, Madrid, Spain

Riquelme, MAR:
 Hosp Guillermo Grant Benavente Concepcion, Serv Hematol, Concepcion, Chile

Lloris, MJS:
 Hosp Dr Peset, Serv Hematol, Valencia, Spain

Algarra-Algarra, L:
 Hosp Gen Albacete, Serv Hematol, Albacete, Spain

Rodriguez-Medina, C:
 Hosp Dr Negrin, Serv Hematol, Las Palmas Gran Canaria, Spain

Melo, CLS:
 Clin Foscal, Serv Hematol, Bucaramanga, Colombia

Gomez, JL:
 Hosp Univ Burgos, Serv Hematol, Burgos, Spain

:
 Hosp U Germans Trias i Pujol, Serv Hematol, Badalona, Spain

Salamero, O:
 Hosp U Vall dHebron, Serv Hematol, Barcelona, Spain

Amigo, ML:
 Hosp Morales Meseguer, Serv Hematol, Murcia, Spain

Nuñez, MV:
 Hosp Arnau Vilanova, Serv Hematol, Valencia, Spain

Rojas, C:
 Hosp Gustavo Fricke, Serv Hematol, Valparaiso, Chile

Bass, F:
 Hosp Salvador, Serv Hematol, Providencia, Chile

García-Fortes, M:
 Hosp U Virgen de la Victoria, Serv Hematol, Malaga, Spain

Vicente, BV:
 Hosp U Salamanca, Serv Hematol, Salamanca, Spain

Polo, M:
 Hosp Clin San Carlos, Serv Hematol, Madrid, Spain

Benavente, C:
 Hosp Clin San Carlos, Serv Hematol, Madrid, Spain

Madrigal, MD:
 Hosp U Virgen de la Macarena, Serv Hematol, Seville, Spain

Espinoza, M:
 Clin Davila, Serv Hematol, Recoleta, Chile

Pérez-Encinas, M:
 Serv Hematol Santiago de Compostela, Santiago De Compostela, Spain

Barciela, MLA:
 Hosp Montecelo, Serv Hematol, Complejo Hosp, Pontevedra, Spain

Bautista, G:
 Hosp Puerta de Hierro, Serv Hematol, Madrid, Spain

Solana-Altabella, A:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Cano-Ferri, I:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Colmenares, R:
 Hosp 12 Octubre, Serv Hematol, Madrid, Spain

García-Ramírez, P:
 Hosp Univ Principe Asturias, Alcala De Henares, Madrid, Spain

Alis, FI:
 Hosp Gen Valencia, Valencia, Spain

García, MB:
 Hosp Carlos Haya, Complejo Hosp Reg Malaga, Malaga, Spain

Rodríguez-Macías, G:
 Hosp Gen Univ Gregorio Maranon, Madrid, Spain

López, M:
 Clin Alemana Santiago, Santiago, Chile

Hernández, AYO:
 Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain

Cerveró, CJ:
 Hosp Virgen de la Luz, Cuenca, Spain

Martínez-Cuadrón, D:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Chorao, P:
 Hosp U La Fe, Serv Hematol, Valencia, Spain

Burgues, JMB:
 Hosp San Pedro de Alcantara, Serv Hematol, Caceres, Spain

Montesinos, P:
 Hosp U La Fe, Serv Hematol, Valencia, Spain
ISSN: 03618609





American Journal of Hematology
Editorial
John Wiley & Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 101 Número: 7
Páginas: 1692-1705
WOS Id: 001746804500001
ID de PubMed: 42017547
imagen hybrid

MÉTRICAS